WO2003034825A1 - Composition anthelmintique - Google Patents
Composition anthelmintique Download PDFInfo
- Publication number
- WO2003034825A1 WO2003034825A1 PCT/JP2002/011067 JP0211067W WO03034825A1 WO 2003034825 A1 WO2003034825 A1 WO 2003034825A1 JP 0211067 W JP0211067 W JP 0211067W WO 03034825 A1 WO03034825 A1 WO 03034825A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- present
- reaction
- fipronil
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
Definitions
- the present invention relates to a parasiticidal composition
- a parasiticidal composition comprising a milbemycin derivative (first component) and a second component as active ingredients, and a method for using the same.
- milbemycin and avermectin-type compounds have excellent insecticidal activity against a wide range of parasites, but milbemycin represented by the following general formula (I) of the present invention ' Derivatives, compositions containing them and their biological activities are hitherto unknown.
- the present inventor has demonstrated that a wide range of ectoparasites including ectoparasites such as fleas, gastrointestinal tract parasites such as roundworm, and endoparasites such as filaria can be strongly affected by both oral and topical administration.
- ectoparasites such as fleas
- gastrointestinal tract parasites such as roundworm
- endoparasites such as filaria
- a composition containing a specific milbemycin derivative and a second component such as praziquantel as an active ingredient shows excellent parasite control activity.
- the present invention has the general formula
- Ri represents a methyl group, an ethyl group, an isopropyl group or an s_butyl group
- R 2 represents an acetyl group, a methoxyacetyl group, a trifluoroacetyl group, a cyanoacetyl group or a methanesulfonyl group. Is shown. ]
- One or two or more first components selected from milbemycin derivatives consisting of a compound represented by or a salt thereof, and
- the present invention relates to a parasiticidal composition containing as an active ingredient one or more second components selected from the group consisting of praziquantel, fipronil, benzimidazoles and neonicotinoids, and a method of using the same.
- the compound represented by the above formula (I), which is an active ingredient of the present invention includes a wide range of ectoparasites including ectoparasites such as fleas, gastrointestinal tract parasites such as roundworms, and endoparasites such as filariae. In addition, it is a compound showing strong activity in both oral and topical administration.
- R i is preferably a methyl group or an ethyl group
- R 2 is preferably a methoxyacetyl group.
- R i is preferably a methyl group or an ethyl group
- R 2 is a methoxyacetyl group
- Representative compounds of the compound (I) which is the active ingredient of the present invention include, for example, the compounds shown in the following table, but the compound (I) is not limited to these compounds.
- stereoisomers may be prepared, for example, by synthesizing compound (I) using the optically resolved raw material compound or, if desired, subjecting the synthesized compound (I) to optical resolution using ordinary optical resolution or separation. can do.
- the compound (I) or a salt thereof, which is an active ingredient of the present invention can be solvated, and such a solvate salt is also included in the active ingredient of the present invention.
- compound (I) may absorb moisture, become adsorbed water, or form a hydrate when left in the air or recrystallized. Salts are also included in the milbemycin derivative which is the active ingredient of the present invention.
- the praziquantel which is an active ingredient of the present invention, is a compound effective against milbemycin and avermectin (Parasitorogy Today, Vol 1, No 1, 10-17, 1985)-a tapeworm, formula
- n 1 for praziquantel and n is 2 for epsiprantel.
- It is a compound represented by these.
- Fipronil such as an active ingredient of the present invention
- the insect is a compound having a arthropod immediate, such as mites, for example, the following formulas ⁇ S- CF 3
- Fipronil represented by the following formula (JP-A-63-316771):
- R when R is a methyl group and X is a chlorine atom, it is acetoprol; when R is an ethyl group and X is a trifluoromethyl group, it is ethylprol. ]
- Benzimidazoles which are the active ingredients of the present invention, are used as a drug for controlling gastrointestinal parasites, and are known, for example, albendazole, flubendazole and mebendazole. anthelmintics-chemistry and biological activity, S. Snarma and S. Auzar, Progress in Drug Research Vol 27, 85-161).
- Neonicotinoids which are the active ingredients of the present invention, include, for example, imidacloprid, thamethoxam, ditenviram and acetamiprid. Among them, imidak-oral pride is a flea controlling agent for topical administration similarly to fipronil. It is used.
- the second component of the present invention is preferably praziquantel or fipronil, more preferably praziquantel, epsiprantel or fipronil.
- the milbemycin derivative which is the active ingredient of the present invention can be produced by the following steps A to D.
- Ri and R2 have the same meanings as described above, and X represents a nitro group or a group represented by the formula —NR 2 H.
- the starting compound a 15-hydroxymilbemycin derivative having the general formula (III), is a known compound described in JP-A-60-158191.
- Step A is carried out by reacting compound (III) in an inert solvent in the presence of trifluoromethanesulfonic acid or its trimethylsilyl ester, which is a strong organic acid, by the general formula
- This is a step of producing a compound represented by the general formula (IV) by reacting a carboxylic acid represented by the following formula:
- the amount of trifluoromethanesulfonic acid or its trimethylsilyl ester to be used is, in principle, a catalytic amount and does not require one equivalent to compound (III), but the reactivity of the carboxylic acid used differs. Can vary significantly.
- an inorganic compound powder when added to the reaction system, the reaction may be accelerated and good results may be obtained.
- inorganic compounds include metal salts such as copper trifluoromethanesulfonate, cuprous iodide, zinc iodide, cobalt iodide, nickel iodide, celite, silica gel, and alumina.
- metal salts such as copper trifluoromethanesulfonate, cuprous iodide, zinc iodide, cobalt iodide, nickel iodide, celite, silica gel, and alumina.
- it is a copper salt such as copper trifluoromethanesulfonate or cuprous iodide, and most preferably, cuprous iodide.
- a silyl ester of a carboxylic acid can be used.
- a method can be used in which a carboxylic acid is reacted with an equivalent amount of aryltrimethylsilane using trifluorenesulfonic acid or its trimethylsilyl ester as a catalyst, and the compound (III) is added to the obtained solution of trimethylsilyl ester.
- the solvent used in the reaction is not particularly limited as long as it does not inhibit the reaction and dissolves the starting material to some extent.
- Preferable examples include aromatic hydrocarbons such as benzene, toluene and xylene; and halogenated hydrocarbons such as methylene chloride, 1,2-dichloroethane and chloroform.
- the reaction temperature is from ⁇ 10 ° to 100 °, preferably from 0 ° to 5 () ⁇ .
- the reaction time varies depending mainly on the reaction temperature, the starting compound and the type of the solvent used, but is usually from 5 minutes to 6 hours, preferably from 10 minutes to 2 hours.
- the compound (IV) is reacted with a reducing agent such as sodium borohydride in an inert solvent to convert the 5-position carbonyl group to a hydroxy group, and the compound represented by the general formula (V) Alternatively, it is a step of producing compound (I) which is an active ingredient of the present invention.
- the reducing agent used is not particularly limited as long as the reducing agent is known to reduce a carbonyl group to a hydroxy group, and may be, for example, a metal boron hydride such as sodium borohydride and porphynium borohydride. Preferably, it is sodium borohydride.
- the reaction solvent can be used without particular limitation as long as it does not participate in the reaction, but the use of ethers such as lower alcohols such as methanol, ethanol, and propanol, tetrahydrofuran, and dimethoxyethane is particularly preferable. .
- the reaction temperature is usually from 0 to 50, and the reaction time is usually from 1 to 10 hours.
- Step C is a step of reducing the nitro group of the compound (V) in an inert solvent to produce a compound represented by the general formula (VI) having an amino group.
- a commonly used method can be used.
- One such example is catalytic reduction using a noble metal catalyst.
- Suitable examples of the catalyst used in the reaction include palladium-carbon, palladium-barium sulfate, platinum oxide and the like.
- Suitable examples of the solvent used for the reaction include alcohols such as methanol and ethanol; ethers such as tetrahydrofuran and dioxane; and esters such as ethyl acetate.
- the reaction temperature is usually 10 to 8 () ⁇ , and the reaction time is usually 10 minutes to 5 hours.
- Another suitable reduction method includes reduction with zinc dust in an acetic acid solvent.
- the reaction temperature is usually from 0 to room temperature, and the reaction time is usually from 30 minutes to 12 hours.
- a more suitable reduction method includes reduction with sodium borohydride in the presence of a nickel catalyst.
- nickel salts such as nickel chloride and nickel bromide can be used, and a triphenylphosphine complex of these nickel salts is preferable.
- Suitable solvents for the reaction include alcohols such as methanol and ethanol; and ethers such as tetrahydrofuran and dioxane.
- the reaction temperature is usually from 0 to room temperature, and the reaction time is usually from about 10 minutes to about 120 minutes.
- Step D comprises, in an inert solvent, an amino group of the compound represented by the compound (VI) and an acid represented by the formula R 2 -OH (wherein R 2 has the same meaning as described above) or This is a step of producing a compound represented by compound (I), which is an active ingredient of the present invention, by reacting the compound with the reactive derivative.
- Examples of the reactive derivative of the acid represented by the formula R 2 —OH include acid halides (acid chloride, acid bromide, etc.), acid anhydrides, mixed acid anhydrides, active esters, active amides, and the like. Usually used ones can be mentioned.
- an acid represented by the formula R 2 —OH for example, dicyclohexyl carpamide (DCC), 2-methyl iodide, 1-methylpyridinium, p-toluenesulfonic acid, sulfuric acid, etc.
- a dehydrating agent is used, and such a dehydrating agent is preferably 2-chloro-1-methylpyridinium iodide.
- the amount of the dehydrating agent to be used is generally 1 to 5 equivalents, preferably 1 to 2 equivalents, relative to the acid represented by the formula R 2 —OH.
- the solvent used is not particularly limited as long as it does not hinder the reaction and dissolves the starting material to some extent, but examples thereof include hydrocarbons such as hexane, petroleum ether, benzene, and toluene; Halogenated hydrocarbons such as form, methylene chloride, 1,2-dichloroethane, ethers such as ethyl ether and tetrahydroplan, amides such as N, N-dimethylformamide, sulfoxides such as dimethyl sulfoxide and Nitriles such as acetonitrile and mixtures of these solvents And preferably dichloromethane or 1,2-dichloroethane.
- hydrocarbons such as hexane, petroleum ether, benzene, and toluene
- Halogenated hydrocarbons such as form, methylene chloride, 1,2-dichloroethane, ethers such as ethyl ether and tetrahydroplan, amides such as N
- the reaction temperature is usually from -70 ports to 9 () ⁇ , and preferably from 0 to 60 ports.
- the reaction time varies depending mainly on the reaction temperature, the starting compound, the reaction reagent or the type of the solvent used, but is usually from 15 minutes to one day and preferably from 30 minutes to 6 hours.
- the reaction is preferably carried out in the presence of a base
- suitable bases include, for example, triethylamine, N, N-dimethylaniline, pyridine, 4-dimethylamino.
- Organic bases such as pyridine, 1,5-diazapicyclo [4.3.0] nonen-5 (DBN) and 1,8-diazapicyclo [5.4.0] indene-17 (DBU).
- the amount of the acid halide used is usually 1 to 10 equivalents to the compound (VI), and the amount of the base used is usually 2 to 8 equivalents.
- the solvent used in the reaction, the reaction temperature, the reaction time and the like are the same as when the carboxylic acid itself is used.
- the reaction temperature is generally 0 to 50, and the reaction time is generally 5 minutes to 2 hours.
- each of the desired compounds (IV), (V) and (I) is isolated from the reaction mixture by a well-known method, and if necessary, a known means such as column chromatography. Purified.
- the natural product milbemycins and their analogous compounds, which are the starting materials of the compound (II), are fermentation products and may be either a single compound or a mixture thereof.
- compound (I) can also be prepared as a single compound or as a mixture.
- the milbemycin derivative which is the active ingredient of the present invention, can be mixed with the other active ingredient, the second ingredient, in a certain ratio, and processed into a formulation suitable for oral or topical administration.
- the combination of the milbemycin derivative and the second component include compound (I) and praziquantel, compound (I) and fipronil, and compound (1), praziquantel and fipronil.
- the compounding ratio of the compounds varies depending on the combination and application. For example, a combination of compound (I) having a weight ratio of 1 to 0.2 of fipronil and 0.5 of prazinitel can be used.
- the compounding ratio of the second component to the compound (I) varies depending on the type and use of the second component used.
- the second component is fipronil, usually 0.1 to 5 is used. Yes, preferably from 0.2 to 1.0, and when the second component is praziquantel, usually from 0.1 to 2, preferably from 0.2 to 0.5.
- the second component is a benzimidazole, it is usually 1.0 to 100, preferably 2.0 to 20, and when the second component is a neonicotinoid, it is usually 0.2. To 10, preferably 0.5 to 2.0.
- the mixing ratio of each component can be set within the above range.
- composition of the present invention When the composition of the present invention is used as an ectoparasiticide in animals or humans, it can be administered orally as a liquid beverage.
- Liquid beverages are usually solutions, suspensions or dispersions in suitable non-toxic solvents or water, with suspending and wetting agents or other excipients such as bentonite.
- Liquid beverages usually contain an antifoaming agent.
- the content of the active ingredient in a beverage formulation such as a liquid beverage is usually 0.01 to 0.5% by mass, and preferably 0.01 to 0.1% by mass.
- compositions of the invention orally in a dry solid unit dosage form
- capsules, pills or tablets containing the desired amount of the active ingredient are usually employed.
- suitable finely divided diluents, fillers, disintegrants and / or binders such as starch, lactose, talc, magnesium stearate, vegetable rubber and the like. It is manufactured by doing.
- suitable finely divided diluents, fillers, disintegrants and / or binders such as starch, lactose, talc, magnesium stearate, vegetable rubber and the like. It is manufactured by doing.
- Such unit dosage regimens can vary widely with respect to the weight and content of the anthelmintic, depending on the type of host animal being treated, the degree of infection, and the type of parasite and the weight of the host.
- composition of the present invention When the composition of the present invention is administered via animal feed, the composition is uniformly dispersed in the feed, used as a top dressing, or used in the form of pellets.
- the content of active ingredient in the final feed to achieve the desired antiparasitic effect is usually from 0.0001 to 0.02% by weight.
- a solution dissolved or dispersed in a liquid carrier excipient can be parenterally administered to animals by injection into the forestomach, intramuscularly, intratracheally or subcutaneously.
- the active ingredients are preferably mixed with a suitable vegetable oil, such as peanut oil, cottonseed oil.
- the amount of active ingredient in such formulations is usually from 0.05 to 50% by weight.
- Still another preferred mode of administration is to dissolve the drug in a solvent and apply it directly to the topic.
- solvents are known to enhance transdermal absorption, such as ethanol, isopropanol, oleyl alcohol, benzyl alcohol, carboxylic acids such as lauric acid and oleic acid, ethyl lactate, and myristic acid.
- esters such as isopropyl and propylene carbonate, sulfoxides such as dimethyl sulfoxide, and amides such as N-methylpyrrolidone.
- the amount of the active ingredient used depends on the type of animal to be treated and the type and degree of the parasitic infection, but is usually from 0.01 to 10 O mg / kg of animal body weight. It is preferably 0.5 to 50.0 mg, and oral administration is desirable. Such dosages can be given in a single or divided dose over a relatively short period of time, such as one to five days.
- composition of the present invention has a high control activity against a wide range of ectoparasites, and exhibits an excellent control effect on insects parasitizing animals and various diseases caused by the parasites.
- composition of the present invention exhibits an excellent insecticidal effect against fleas parasitic on pet humans, and is extremely effective as a pesticide for these.
- target fleas examples include a cat flea (Ctenocephalides felis) and a flea (Ctenocephalides canis).
- compositions of the present invention can be used against a variety of harmful animal parasites (endo and ecto parasites), such as insects and helminths.
- animal parasites include Gasterophilus (Gasterophilus spp.), Sashibae (Stomoxys spo.), Roe and Nuff (Tnchodectes spp. No., Pacific turtle (Rhodnius sop. No., Hypoderma spp.) , Hidge flies (Oestrus spp.) And lice (Haematopinus spp.) And the like.
- composition of the J * invention includes a tick family (Ixodidae), a mimetic family (Dermanyssid-ae), a sarcophaga family (Sarcoptidae), a sarcophaga family (Argasidae), a sarcophaga family (Demodicidae) and a squash family parasitizing animals. (Psoroptidae) and the like.
- composition of the present invention has excellent parasiticidal activity as an anthelmintic for animals and humans, especially livestock, poultry and pets such as pigs, sheep, goats, cattle, horses, dogs, cats and chickens. It is effective against nematodes that infect worms.
- Such nematodes include, for example, Haemonchus, Trichostrongylus, Ostertagia, Nematodirus, Cooperia, Cascalis ( Ascaris), Bunostomum, Oesophagostomum, Chabertia, Trichuris, Trichoris, Storongylus, Trichonema, Dicho (Dictyocaulus), Capillaria, Heterakis, Toxocara, Ascaridia, Oxyuris, Ancylostoma, Uncinaria Mention may be made of Toxascaris and Parascaris.
- compositions of the present invention also exhibit activity.
- the parasites of the family Filariidae and Setariidae are found in other tissues and organs, such as heart and vascular, subcutaneous and lymphatic tissues, and the compositions of the present invention are also active on these. Is shown.
- compositions of the present invention are also active against tapeworms and flukes.
- tapeworms include canine tapeworms (Dipylidium caninum), three shoot tapeworms (Taenia taeniaeformis)> tapered tapeworms (Taenia solium), hookless tapeworms (Taenia saginata), and fe microtape (Hymenolepis diminuta).
- composition of the present invention is also useful against parasites that infect humans.
- human digestive tract parasites include Ancylostoma, Necator, and Ascaris. Asdaris), Strongyloides, Trichinella, Capillaria, Richuris and Enterobius.
- compositions of the present invention are of the genus Wuchereria, Blu-Jia of the family Filariae, other medically important parasites found in the blood or other tissues and organs outside the gastrointestinal tract.
- Brugia Onchoceca, Dirofilaria, and Loa
- special species of the parasites of the genus Deacunculus and the intestinal parasites of the genus Deracunculus (Dracunculidae). It is also active against Strongyreutes and Trichinella in extraintestinal parasites.
- composition of the present invention will be described in more detail with reference to Reference Examples and Test Examples, but the composition of the present invention is not limited thereto.
- Step A Dissolve the 5-oxo compound obtained in Step A in methanol (200 ml), and add sodium borohydride (1.52 g, 40 mmol) and boron trifluoride / ether adduct (2 drops) at -40 ports. The mixture was stirred for 10 minutes. After completion of the reaction, ethyl acetate (400 ml) was added to the reaction solution, washed with water three times, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
- the nitro compound obtained in (2) was dissolved in ethyl acetate (100 ml), and methanol (100 ml) and a triphenylphosphine complex of nickel (II) chloride (1.12 g, 1.7 mmol) were added.
- Sodium borohydride 100 mg, 2.6 mmol was added slowly over 10 minutes.
- ethyl acetate 70 ml was added to the reaction solution, washed three times with water, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
- the combined use of the compound of Reference Example 1 and fipronil was effective for the treatment of mite infection, despite the small dose of fipronil.
- single use of the compound of Reference Example 1 was ineffective in treating mite infection.
- the use of fipronil alone was ineffective at treating mite infections at low doses.
- composition of the present invention has a high control activity against a wide range of ectoparasites, and exhibits an excellent control effect on insects parasitizing animals and various diseases caused by the parasites.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Agronomy & Crop Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR0213550-7A BR0213550A (pt) | 2001-10-25 | 2002-10-24 | Composição anti-helmìntica |
IL16156002A IL161560A0 (en) | 2001-10-25 | 2002-10-24 | Anthelmintic compositions containing milbemycin derivatives |
NZ532977A NZ532977A (en) | 2001-10-25 | 2002-10-24 | Anthelmintic composition |
HU0401677A HUP0401677A2 (hu) | 2001-10-25 | 2002-10-24 | Parazitaellenes készítmény és alkalmazása |
KR10-2004-7006104A KR20040047962A (ko) | 2001-10-25 | 2002-10-24 | 기생충 구제 조성물 |
EP02773008A EP1449435A4 (en) | 2001-10-25 | 2002-10-24 | WORMERS |
MXPA04003854A MXPA04003854A (es) | 2001-10-25 | 2002-10-24 | Composicion antihelmintica. |
CA002464403A CA2464403A1 (en) | 2001-10-25 | 2002-10-24 | Anthelmintic composition |
AU2002338201A AU2002338201B2 (en) | 2001-10-25 | 2002-10-24 | Anthelmintic composition |
US10/493,716 US20040254125A1 (en) | 2001-10-25 | 2002-10-24 | Anthelmintic composition |
NO20041671A NO20041671L (no) | 2001-10-25 | 2004-04-22 | Anthelmintic composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001327198 | 2001-10-25 | ||
JP2001-327198 | 2001-10-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003034825A1 true WO2003034825A1 (fr) | 2003-05-01 |
Family
ID=19143465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/011067 WO2003034825A1 (fr) | 2001-10-25 | 2002-10-24 | Composition anthelmintique |
Country Status (17)
Country | Link |
---|---|
US (1) | US20040254125A1 (ja) |
EP (1) | EP1449435A4 (ja) |
KR (1) | KR20040047962A (ja) |
CN (1) | CN1592577A (ja) |
AU (1) | AU2002338201B2 (ja) |
BR (1) | BR0213550A (ja) |
CA (1) | CA2464403A1 (ja) |
CO (1) | CO5580745A2 (ja) |
HU (1) | HUP0401677A2 (ja) |
IL (1) | IL161560A0 (ja) |
MX (1) | MXPA04003854A (ja) |
NO (1) | NO20041671L (ja) |
NZ (1) | NZ532977A (ja) |
PL (1) | PL370227A1 (ja) |
RU (1) | RU2004115744A (ja) |
WO (1) | WO2003034825A1 (ja) |
ZA (1) | ZA200403323B (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050192319A1 (en) * | 1996-09-19 | 2005-09-01 | Albert Boeckh | Spot-on formulations for combating parasites |
US20090281175A1 (en) * | 2006-09-28 | 2009-11-12 | Galderma S.A. | Avermectin compounds and treatment of dermatological disorders in humans therewith |
TW200924647A (en) | 2007-08-30 | 2009-06-16 | Schering Plough Ltd | Local topical administration formulations containing fipronil |
GB2457734A (en) * | 2008-02-25 | 2009-08-26 | Norbrook Lab Ltd | Topical phenyl pyrazole insecticide composition |
BRPI0802255A2 (pt) * | 2008-06-17 | 2010-03-16 | Sespo Ind E Com Ltda | composição de uso tópico para controle de ectoparasitos em cães e gatos |
EP2416663A2 (en) | 2009-03-18 | 2012-02-15 | Martin Benedict George Donnelly | Parasiticidal formulation |
GB0905365D0 (en) | 2009-03-27 | 2009-05-13 | Norbrook Lab Ltd | A topical parasiticide composition |
UA108641C2 (uk) | 2010-04-02 | 2015-05-25 | Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування | |
JO3626B1 (ar) | 2012-02-23 | 2020-08-27 | Merial Inc | تركيبات موضعية تحتوي على فيبرونيل و بيرميثرين و طرق استخدامها |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA842571B (en) | 1983-04-07 | 1985-11-27 | Merck & Co Inc | Novel synergistic antiparasitic combinations |
EP0765879A1 (en) | 1995-09-29 | 1997-04-02 | Sankyo Company Limited | 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests |
WO1998006407A1 (en) | 1996-07-30 | 1998-02-19 | Ashmont Holdings Limited | Anthelmintic formulations |
WO1998011780A1 (fr) | 1996-09-19 | 1998-03-26 | Merial | Nouvelle association parasiticide |
JPH10152407A (ja) * | 1996-09-24 | 1998-06-09 | Sankyo Co Ltd | 樹幹注入剤 |
AU694016B2 (en) | 1995-05-10 | 1998-07-09 | Virbac (Australia) Pty Limited | Canine anthelmintic preparation |
US6159932A (en) * | 1995-06-02 | 2000-12-12 | Bayer Aktiengesellschaft | Endoparasiticidal compositions |
EP1066854A2 (en) | 1999-07-08 | 2001-01-10 | Pfizer Inc. | Anthelmintic compositions containing combinations of avermectins or milbemycins with bis-aryl compounds |
WO2001083500A1 (en) | 2000-04-27 | 2001-11-08 | Sankyo Company, Limited | 13-substituted milbemycin derivatives, their preparation and their use against insects and other pests |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR8701302A (pt) * | 1986-03-25 | 1987-12-22 | Sankyo Co | Compostos macrolideos,sua preparacao e seu uso |
US4831016A (en) * | 1986-10-31 | 1989-05-16 | Merck & Co., Inc. | Reduced avermectin derivatives |
US5428034A (en) * | 1988-09-02 | 1995-06-27 | Sankyo Co., Ltd. | Milbemycin derivatives, their preparation and their use |
US5276033A (en) * | 1991-12-18 | 1994-01-04 | Sankyo Company, Limited | 13-(substituted thio)acetoxymilbemycin derivatives, their preparation and their agrochemical uses |
US6426333B1 (en) * | 1996-09-19 | 2002-07-30 | Merial | Spot-on formulations for combating parasites |
US6998131B2 (en) * | 1996-09-19 | 2006-02-14 | Merial Limited | Spot-on formulations for combating parasites |
MXPA01007963A (es) * | 1999-02-09 | 2004-01-29 | Kitasato Inst | Derivados de evermectin. |
US6500463B1 (en) * | 1999-10-01 | 2002-12-31 | General Mills, Inc. | Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles |
-
2002
- 2002-10-24 BR BR0213550-7A patent/BR0213550A/pt not_active IP Right Cessation
- 2002-10-24 AU AU2002338201A patent/AU2002338201B2/en not_active Ceased
- 2002-10-24 MX MXPA04003854A patent/MXPA04003854A/es unknown
- 2002-10-24 WO PCT/JP2002/011067 patent/WO2003034825A1/ja active IP Right Grant
- 2002-10-24 EP EP02773008A patent/EP1449435A4/en not_active Withdrawn
- 2002-10-24 KR KR10-2004-7006104A patent/KR20040047962A/ko not_active Application Discontinuation
- 2002-10-24 RU RU2004115744/04A patent/RU2004115744A/ru not_active Application Discontinuation
- 2002-10-24 CN CNA028235002A patent/CN1592577A/zh active Pending
- 2002-10-24 HU HU0401677A patent/HUP0401677A2/hu unknown
- 2002-10-24 PL PL02370227A patent/PL370227A1/xx not_active Application Discontinuation
- 2002-10-24 IL IL16156002A patent/IL161560A0/xx unknown
- 2002-10-24 NZ NZ532977A patent/NZ532977A/en unknown
- 2002-10-24 US US10/493,716 patent/US20040254125A1/en not_active Abandoned
- 2002-10-24 CA CA002464403A patent/CA2464403A1/en not_active Abandoned
-
2004
- 2004-04-22 NO NO20041671A patent/NO20041671L/no not_active Application Discontinuation
- 2004-05-03 ZA ZA200403323A patent/ZA200403323B/xx unknown
- 2004-05-21 CO CO04047506A patent/CO5580745A2/es not_active Application Discontinuation
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA842571B (en) | 1983-04-07 | 1985-11-27 | Merck & Co Inc | Novel synergistic antiparasitic combinations |
AU694016B2 (en) | 1995-05-10 | 1998-07-09 | Virbac (Australia) Pty Limited | Canine anthelmintic preparation |
US6159932A (en) * | 1995-06-02 | 2000-12-12 | Bayer Aktiengesellschaft | Endoparasiticidal compositions |
EP0765879A1 (en) | 1995-09-29 | 1997-04-02 | Sankyo Company Limited | 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests |
WO1998006407A1 (en) | 1996-07-30 | 1998-02-19 | Ashmont Holdings Limited | Anthelmintic formulations |
WO1998011780A1 (fr) | 1996-09-19 | 1998-03-26 | Merial | Nouvelle association parasiticide |
JPH10152407A (ja) * | 1996-09-24 | 1998-06-09 | Sankyo Co Ltd | 樹幹注入剤 |
EP1066854A2 (en) | 1999-07-08 | 2001-01-10 | Pfizer Inc. | Anthelmintic compositions containing combinations of avermectins or milbemycins with bis-aryl compounds |
WO2001083500A1 (en) | 2000-04-27 | 2001-11-08 | Sankyo Company, Limited | 13-substituted milbemycin derivatives, their preparation and their use against insects and other pests |
Non-Patent Citations (1)
Title |
---|
See also references of EP1449435A4 |
Also Published As
Publication number | Publication date |
---|---|
NO20041671L (no) | 2004-07-16 |
CA2464403A1 (en) | 2003-05-01 |
CN1592577A (zh) | 2005-03-09 |
EP1449435A1 (en) | 2004-08-25 |
AU2002338201B2 (en) | 2007-06-28 |
PL370227A1 (en) | 2005-05-16 |
CO5580745A2 (es) | 2005-11-30 |
ZA200403323B (en) | 2004-11-08 |
IL161560A0 (en) | 2004-09-27 |
MXPA04003854A (es) | 2005-02-17 |
RU2004115744A (ru) | 2005-04-10 |
HUP0401677A2 (hu) | 2004-12-28 |
KR20040047962A (ko) | 2004-06-05 |
EP1449435A4 (en) | 2005-01-05 |
NZ532977A (en) | 2007-01-26 |
US20040254125A1 (en) | 2004-12-16 |
BR0213550A (pt) | 2004-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2669635B2 (ja) | アベルメクチン誘導体 | |
KR960006391B1 (ko) | 13-치환된 밀베마이신 유도체, 그의 제조 및 용도 | |
JP2505901B2 (ja) | アベルメクチン誘導体 | |
JP2509560B2 (ja) | 新規なアベルメクチンアグリコンの置換された又は置換されていない13―(アルコキシ)メトキシ誘導体 | |
JPS58167591A (ja) | 4”―アミノ―4”―デオキシアベルメクチン化合物及びその置換アミノ誘導体 | |
JPH085894B2 (ja) | ミルベマイシンエーテル誘導体 | |
US5595991A (en) | Anthelmintic use of nodulisporic acid and analogs thereof | |
JPH0753734B2 (ja) | アベルメクチンおよびミルベマイシンの13−ケト,13−イミノ,および13−アミノ誘導体 | |
JPH11509550A (ja) | 駆虫薬マルクホルチンおよびパラヘルクアミド | |
JPH0822870B2 (ja) | 4″−デオキシ−4″−エピ−メチルアミノアベルメクチンBla/Blbの安定塩 | |
JP3135918B2 (ja) | 活性抗寄生虫剤としてのアルキルチオアルキルアベルメクチン | |
JPH089623B2 (ja) | 4a−置換アベルメクチン誘導体 | |
JPH0516431B2 (ja) | ||
WO2003034825A1 (fr) | Composition anthelmintique | |
JPH02212491A (ja) | アベルメクチン誘導体 | |
KR0168848B1 (ko) | 밀베마이신 에테르 유도체, 그의 제법 및 그의 치료적 및 농화학적 용도 | |
JP2583946B2 (ja) | モノ−及びジエポキシll−f28249化合物の23−オキソ(ケト)及び23−イミノ誘導体 | |
JP2003201204A (ja) | 寄生虫駆除組成物 | |
JP2703551B2 (ja) | Ll−f28249化合物のモノ−及びジエポキシド誘導体 | |
JPH02264778A (ja) | アベルメクチン誘導体 | |
US5240915A (en) | Avermectin derivatives | |
JPS63264586A (ja) | Ll−f28249化合物の23−デオキシ−27−ハロ(クロロ又はブロモ)誘導体 | |
JPS63270685A (ja) | Ll−f28249化合物の27−ハロゲン化誘導体 | |
JPH0250913B2 (ja) | ||
JP2003064082A (ja) | アベルメクチン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 161560 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/003854 Country of ref document: MX Ref document number: 2464403 Country of ref document: CA Ref document number: 1020047006104 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/03323 Country of ref document: ZA Ref document number: 200403323 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10493716 Country of ref document: US Ref document number: 2002338201 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 602/KOLNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 532977 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 04047506 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002773008 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028235002 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002773008 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002338201 Country of ref document: AU |